APA

Martin L. P., Konner J. A., Moore K. N., Seward S. M., Matulonis U. A., Perez R. P., Su Y., Berkenblit A., Ruiz-Soto R. & Birrer M. J. (20171108). Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. : Gynecologic oncology.

Chicago

Martin Lainie P, Konner Jason A, Moore Kathleen N, Seward Shelly M, Matulonis Ursula A, Perez Raymond P, Su Ying, Berkenblit Anna, Ruiz-Soto Rodrigo and Birrer Michael J. 20171108. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. : Gynecologic oncology.

Harvard

Martin L. P., Konner J. A., Moore K. N., Seward S. M., Matulonis U. A., Perez R. P., Su Y., Berkenblit A., Ruiz-Soto R. and Birrer M. J. (20171108). Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. : Gynecologic oncology.

MLA

Martin Lainie P, Konner Jason A, Moore Kathleen N, Seward Shelly M, Matulonis Ursula A, Perez Raymond P, Su Ying, Berkenblit Anna, Ruiz-Soto Rodrigo and Birrer Michael J. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. : Gynecologic oncology. 20171108.